<DOC>
	<DOCNO>NCT00833040</DOCNO>
	<brief_summary>The purpose research study evaluate ARX-F02 ( Sufentanil NanoTab ) versus placebo ( `` sugar '' pill inactive substance ) management breakthrough pain cancer patient .</brief_summary>
	<brief_title>A Study Evaluation Safety , Tolerability , Efficacy ARX-F02 ( Sufentanil NanoTab ) Compared Placebo Treatment Cancer Breakthrough Pain</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Sufentanil</mesh_term>
	<criteria>1 . Patients 18 year age older document clinical history evidence malignancy . 2 . Patients must sufficient pain require least equivalent 60 mg/day oral morphine , least 25 mcg/hr transdermal fentanyl , least 30 mg/day oxycodone , least 8 mg/day oral hydromorphone week longer . 3 . Patient experience 1 4 episode cancer breakthrough pain per day , average necessarily every day , require use additional opioid analgesic . 4 . Patient life expectancy least 3 month . 5 . Patient must Eastern Cooperative Oncology Group ( ECOG ) performance status rating &lt; 2 . 6 . Patient must able provide reliable documentation pain intensity , pain relief , use rescue medication , global evaluation treatment personally help caregiver . 7 . Patient must able enter simple command Palm Pilot device , personally help caregiver . 8 . If patient female childbearing potential must negative urine pregnancy test screening , must use medically acceptable method birth control . Acceptable method birth control include oral transdermal contraceptive , condom , spermicidal foam , IUD , progestin implant injection , abstinence , vaginal ring , sterilization partner . The reason nonchildbearing potential , bilateral tubal ligation , bilateral oophorectomy , hysterectomy , 1 year postmenopausal must specify patient 's CRF . 9 . Patient must demonstrate dexterity handle singledose applicator use place NanoTab™ tongue . 10 . Patient and/or caregiver must demonstrate ability use NanoTab™ retrieval tool . 11 . There must caregiver home ( hospice ) present least 1 hour follow dose titration . 12 . Patient must provide write informed consent . 1 . Patients uncontrollable rapidly escalate pain . 2 . Patients history psychiatric disease loss cognitive function would prevent patient provide reliable study documentation . 3 . Patients oral mucositis stomatitis . 4 . Patients history substance abuse within past year . 5 . Patients use intrathecal opioids . 6 . Patients underlie pulmonary disease sleep apnea chronic obstructive pulmonary disease characterize CO2 retention deem clinically significant investigator . 7 . Patients risk significant bradyarrhythmia , opinion Investigator , due underlie heart disease . 8 . Patients abnormal chemistry hematology deem investigator clinically significant . Abnormalities cancer relate document . 9 . Patients clinically significant abnormality Screening ECG , Investigator 's opinion , participate study . 10 . Patients receive chemotherapy radiation treatment 3week titration phase 3week doubleblind phase , Investigator 's opinion , may dramatically alter patient 's pain level response pain medication . 11 . Patients take monoamine oxidase inhibitor ( MAOIs ) , take MAOIs within 14 day prior enrol study . 12 . Patients participate clinical trial investigational drug device within 30 day screen visit . 13 . Patients , Investigator 's opinion , participate study may capable follow study schedule procedure reason . 14 . Patients employee family member Investigator , study center AcelRx .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Cancer breakthrough pain</keyword>
</DOC>